This application protects the method of composition and method of use of Prima’s CVac for the generation of a cytotoxic T cell response against the mucin 1 antigen.
CVac is a personalised immunotherapy composed of patients’ own dendritic cells pulsed with the cancer antigen mucin 1, conjugated to oxidised mannan fusion protein. The pulsed dendritic cells are then reinjected into the patient to stimulate an immune response to the mucin 1 cancer antigen.
Prima BioMed CEO Matthew Lehman said that the allowance of this key USA patent is a significant milestone.
"The grant of the USA patent would complete the granting of all pending applications relating to the Company’s intellectual property portfolio," Lehman added.